TY - JOUR
T1 - ADA-EASD diabetes guidance
T2 - individualised treatment of hyperglycaemia
AU - Day, Caroline
PY - 2012/5
Y1 - 2012/5
N2 - Hyperglycaemia is a significant contributor to the morbidity and premature mortality of type 2 diabetes. There are several glucose lowering agents, with each class having a different mechanisms of action, but their utilisation has to be considered within the context of disease pathogenesis; appropriateness of the agent for the patient, patient lifestyle and personal circumstance, and to some extent treatment costs. The most recent joint policy statement from the American Diabetes Association and the European Association for the Study of Diabetes addresses these issues and provides guidance on strategies for a patient centred approach to the implementation of evidence based medicine. Glycaemic targets are flexible, but early intervention, and therapy as intensive as individual circumstance dictates are recommended.
AB - Hyperglycaemia is a significant contributor to the morbidity and premature mortality of type 2 diabetes. There are several glucose lowering agents, with each class having a different mechanisms of action, but their utilisation has to be considered within the context of disease pathogenesis; appropriateness of the agent for the patient, patient lifestyle and personal circumstance, and to some extent treatment costs. The most recent joint policy statement from the American Diabetes Association and the European Association for the Study of Diabetes addresses these issues and provides guidance on strategies for a patient centred approach to the implementation of evidence based medicine. Glycaemic targets are flexible, but early intervention, and therapy as intensive as individual circumstance dictates are recommended.
KW - ADA
KW - consensus
KW - EASD
KW - hyperglycaemia
KW - individualisation
KW - type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=84862993782&partnerID=8YFLogxK
UR - http://dvd.sagepub.com/content/12/3/146
U2 - 10.1177/1474651412450477
DO - 10.1177/1474651412450477
M3 - Article
AN - SCOPUS:84862993782
SN - 1474-6514
VL - 12
SP - 146
EP - 151
JO - British Journal of Diabetes and Vascular Disease
JF - British Journal of Diabetes and Vascular Disease
IS - 3
ER -